10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Switzerland-based biotech firm Numab Therapeutics has entered into a research collaboration and worldwide licensing agreement with German family-owned pharma Boehringer Ingelheim. 7 July 2020
Immuno-oncology start-up Vor Biopharma, which is pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced it has raised $110 million in a Series B financing. 7 July 2020
US biotech firm Regeneron Pharmaceuticals saw its shares rise 4.6% on Monday and gain a further 3.6% to $650.03 by mid-morning today, after it announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron's investigational double antibody cocktail for the treatment and prevention of COVID-19, as well as a lucrative deal with the US government. 7 July 2020
The European Investment Bank (EIB) and CureVac, a clinical-stage German biotech company developing a new class of transformative medicines based on optimised mRNA, entered into a 75 million-euros ($84 million) loan agreement to support the company’s ongoing development of vaccines against infectious diseases, including its vaccine candidate CVnCoV aimed at preventing SARS-CoV-2 infections. 7 July 2020
Shares in Immunomedics were lifted 8% on Monday, after the antibody-drug conjugate (ADC) specialist posted positive data from the Phase III ASCENT study of Trodelvy (sacituzumab govitecan-hziy). 7 July 2020
Emergent BioSolutions has announced a five-year manufacturing services agreement with Janssen Pharmaceuticals, part of US healthcare giant Johnson & Johnson, for large-scale drug substance manufacturing for J&J’s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac technology. 7 July 2020
US biopharma Unum Therapeutics has completed the acquisition of Kiq, a privately-held biotech focused on the discovery and development of precision kinase inhibitors. 6 July 2020
Cambridge, USA-based Dragonfly Therapeutics today announced a new research collaboration with Bristol-Myers Squibb to discover and develop Dragonfly's novel immunotherapies for multiple sclerosis and neuro-inflammation targets. 6 July 2020
Swiss oncology-focused drug discovery firm ADC Therapeutics today announced that the US Food and Drug Administration has lifted the partial clinical hold on the pivotal Phase II clinical trial of camidanlumab tesirine (Cami, formerly ADCT-301) in patients with relapsed or refractory Hodgkin lymphoma (HL). 6 July 2020
UK-based drug discovery and development company Mission Therapeutics, which is focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announced that it has raised $15 million in equity investment. 6 July 2020
Swiss biotech Idorsia today announced positive top-line results of the second pivotal Phase III study investigating 10mg and 25mg doses of its dual orexin receptor antagonist, daridorexant, in 924 adult and elderly patients (39.3% ≥ 65 years) with insomnia. 6 July 2020
The specialist HIV company ViiV Healthcare, which is majority owned by GlaxoSmithKline, has announced that the US Food and Drug Administration (FDA) has approved Rukobia (fostemsavir), 600 mg extended-release tablets. 3 July 2020
CSL Behring has announced that the European Medicines Agency (EMA) has approved the new Summary of Product Characteristics, which includes information about new, extended dosing options, for Idelvion (coagulation Factor IX [recombinant], albumin fusion protein; albutrepenonacog alfa). 3 July 2020
The US Phase III trial of rheumatoid arthritis drug Kevzara (sarilumab) in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints when Kevzara was added to best supportive care compared to best supportive care alone (placebo). 3 July 2020
The US Food and Drug Administration has approved a randomized, double-blind, placebo-controlled Phase III clinical trial protocol to evaluate the safety and efficacy of intravenous siltuximab plus standard of care in hospitalized patients with COVID-19 associated acute respiratory distress syndrome (ARDS). 2 July 2020
Hopes for an effective vaccine against the novel coronavirus have been boosted by positive Phase I/II data from the BNT162 mRNA-based vaccine program. 2 July 2020
US clinical-stage immuno-oncology firm EpicentRx has entered into a licensing agreement for RRx-001, a small molecule immunotherapy targeting CD47 – SIRPα with ongoing Phase III trial in small cell lung cancer (SCLC), with China-owned SciClone Pharmaceuticals International. 1 July 2020
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024